Anti-Coagulants - Italy

Italy

Highlights

The revenue in the Anti-Coagulants market in Italy is projected to reach US$517.50m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 6.82%, resulting in a market volume of US$719.70m by 2029.
In global comparison, United States is expected to generate the most revenue, with US$16.74bn in 2024.
Italy's growing elderly population and high prevalence of cardiovascular diseases make it a key market for anti-coagulants.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in Italy has been experiencing several trends and developments in recent years.

Customer preferences: Patients in Italy have been increasingly preferring direct oral anticoagulants (DOACs) over traditional anticoagulants due to their convenience and ease of use. DOACs have also been associated with lower rates of major bleeding events compared to traditional anticoagulants, which has further contributed to their popularity among patients.

Trends in the market: The Anti-Coagulants market in Italy has been witnessing a shift towards DOACs in recent years. This trend is expected to continue as DOACs gain more widespread acceptance among physicians and patients. The market for DOACs is also expected to grow due to the increasing prevalence of atrial fibrillation and venous thromboembolism in Italy.

Local special circumstances: The Italian healthcare system has been facing several challenges in recent years, including budget constraints and an aging population. These challenges have led to the implementation of cost containment measures, which have affected the Anti-Coagulants market in Italy. As a result, there has been increased pressure on pharmaceutical companies to provide cost-effective treatments that can be accessed by a larger population.

Underlying macroeconomic factors: Italy has been facing economic challenges in recent years, including high levels of public debt and low economic growth. These factors have had an impact on the Anti-Coagulants market in Italy, as patients and healthcare providers are increasingly looking for cost-effective treatments. This has led to a greater emphasis on the use of generic drugs and the implementation of cost containment measures in the healthcare sector. In conclusion, the Anti-Coagulants market in Italy has been experiencing a shift towards DOACs due to their convenience and lower risk of bleeding events. However, the market is also facing challenges due to budget constraints and cost containment measures in the healthcare sector. Despite these challenges, the market for Anti-Coagulants in Italy is expected to continue to grow due to the increasing prevalence of atrial fibrillation and venous thromboembolism in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.